Veriti Management LLC Bei Gene, Ltd. Transaction History

Veriti Management LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 05, 2024	SELL	$158.67 - $201.58 $68,704 - $87,284	-433 Reduced 13.36%	2,808 $506,000
Q3 2023 Oct 27, 2023	SELL	$179.87 - $225.13 $59,357 - $74,292	-330 Reduced 9.24%	3,241 $582,000
Q2 2023 Jul 13, 2023	SELL	$178.3 - $266.78 $110,546 - $165,403	-620 Reduced 14.79%	3,571 $636,000
Q1 2023 Apr 26, 2023	BUY	$215.53 - $274.5 $58,193 - $74,115	270 Added 6.89%	4,191 $903,000
Q4 2022 Jan 20, 2023	BUY	$125.51 - $229.3 $268,842 - $491,160	2,142 Added 120.4%	3,921 $0
Q3 2022 Oct 26, 2022	SELL	$131.8 - $202.24 $37,035 - $56,829	-281 Reduced 13.64%	1,779 $240,000
Q2 2022 Jul 18, 2022	BUY	$121.11 - $216.05 $249,486 - $445,063	2,060 New	2,060 $333,000

251

45.3M

292K

119K

Ticker BGNE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 103,700,000
Market Cap $23.5B
Description
BeiGene, Ltd., a biotechnology company, focuses on discovering, developing, manufacturing, and commercializing various medicines worldwide. Its products include BRUKINSA to treat relapsed/refractory (R/R) mantle cell lymphoma; Tislelizumab to treat R/R classical Hodgkin's lymphoma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplas...

Get notified when there are updates to the investment portfolio of Veriti Management LLC, based on Form 13F filings with the SEC.

Stay updated on Veriti Management LLC with notifications on news.